BLCM

BLCM - Bellicum Pharmaceuticals Inc Stock Price, Fair Value and News

$0.07 
Market Closed as of 04 Mar 2024, 04:00 pm ET

BLCM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLCM Price Action

BLCM RSI Chart

BLCM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLCM Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BLCM Fundamentals

BLCM Revenue

BLCM Earnings

BLCM Profitability

BLCM Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2023----
20224.6M-3.1M1.5M
20211.9M3.4M4.8M6.2M
20207.0M--500.0K
20191.5M2.5M2.3M7.1M
2018418.8K652.5K886.3K1.1M
2017424.0K323.0K335.0K185.0K
2016267.0K284.0K341.0K388.0K
20151.3M865.5K262.5K282.0K
20141.9M1.9M1.8M1.8M
2013---1.9M
BLCM
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
 WEBSITEbellicum.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES13